- KYPROLIS® (carfilzomib) is indicated in combination with dexamethasone, or with lenalidomide plus dexamethasone, or with daratumumab plus dexamethasone, ... Read More Read Less
Adverse events were consistent with the known safety profiles of each medication.1,2
Most common adverse reactions (≥ 20% incidence) in Isa-Kd vs Kd arms1,2
The most frequent serious adverse reactions in > 5% of patients who received Isa-Kd were pneumonia (25%) and upper respiratory tract infections (9%).
Isa-Kd = carfilzomib + isatuximab-irfc + dexamethasone; Kd = carfilzomib + dexamethasone; AE = adverse event.
Please see accompanying full Prescribing Information.
Please see accompanying full Prescribing Information.
References: 1. Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397(10292):2361-2371. 2. SARCLISA® (isatuximab-irfc) prescribing information. Bridgewater, NJ: sanofi-aventis U.S. LLC.